RankAlpha logo
Back to Rankings

CRL

Charles River Laboratories InternationalA
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The constructive case is that CRL has already reaffirmed 2026 guidance, says DSA demand is tracking expectations, and has a clearer portfolio after divestitures, with an added AI/NAM positioning angle from TuneLab [#SEC-8K-2026-05-07] [#IR-2026-06-18].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Non-GAAP operating margin fell to 16.3% in Q1 because of higher DSA study-related direct costs, unfavorable RMS mix, and higher stock-based compensation [#SEC-8K-2026-05-07].
Momentum
91
Value
62
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $220.00 · Bull $255.00 · Bear $185.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-01 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $237.79
Why
Momentum91 · Δ7d -4.1
Value62 · Δ7d +0.2
Sentiment45 · Δ7d +0.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
91
26% active weight
Current posture
7d trendFlat
Δ7d
-4.1
Δ21d
+2.9
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.1
Sentiment
45
34% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+5.5
Why this grade

Composite grade A. Momentum 90.5 / Value 61.6 / Sentiment 44.7

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$10.58B
Beta
1.63
Shares Out
48.17M
P/E (TTM) · Derived
-75.4
P/S (TTM)
2.55
P/FCF (TTM)
18.86
Rev YoY
+1.2%
EPS YoY
-160.5%
Gross Margin
+31.3%
Op Margin
+3.5%
Net Debt
$2.42B
Current Ratio
1.36
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology